Spanish National Center for Cardiovascular Research (CNIC)

A new therapy for the treatment of myeloproliferative diseases

Posted by CNIC from Spanish National Center for Cardiovascular Research (CNIC)Responsive · Patents for licensing · Spain

Summary of the technology

Myelodysplastic/myeloproliferative neoplasms (MPN) are a group of diseases that affect normal blood cell production in the bone marrow. In this case the bone marrow causes an overproduction of one or more blood cell types (red cells, white cells or platelets). Complications arise over time due to the abnormally high number of blood cells that accumulate in the bone marrow and in the circulating blood. In many cases, these diseases develop slowly and get worse gradually. In some cases, MPN can progress to leukemia. Compounds capable of preventing and treating these types of diseases are urgently needed.

CNIC researchers have identified new therapeutic targets based on alterations in the regulation of mesenchymal stem cells (MSC) in the hematopoietic niche by sympathetic nerves. They have also defined an in vitro method for prognosis/diagnosis of MPNs and/or to define the disease´s stage, and a method to screen for therapeutic compounds useful to treat MPNs.

Spanish National Center for Cardiovascular Research (CNIC)

Description of the technology

CNIC researchers have described the neural mechanisms regulating the hematopoietic niche, regulatory mechanisms that are impaired in myeloproliferative neoplasms and that contribute to the disease´s pathogenesis, thereby emerging as new therapeutic targets. They have demonstrated that production of Interleukin-1 beta by mutant progenitors can damage the Schwann cells that protect sympathetic nerve endings in the bone marrow. This neuroglial damage enhances the susceptibility of mesenchymal stem cell in the hematopoietic niche to cell death caused by mutant hematopoietic cells. They have showed that CXCL12, a chemokine produced by nestin MSCs, can partially control the expansion of the mutant hematopoietic progenitors. The decrease in MSCs in the bone marrow and the concomitant decrease in CXCL12 levels in MPN accelerates disease progression. The use of neurotrophic agents that prevent or rescue neuro-glial damage, together with beta3-adrenergic agonists, which make up for the deficit of sympathetic stimulation of nestin MSCs, can control the expansion of leukemic stem cells and arrest disease progression. Therefore, they have proved the existence of a sympathetic neuropathy in MPN affecting the hematopoietic niche in the bone marrow, which plays an essential role in MPN pathogenesis and has consequently emerges as a new therapeutic target.

Applications

- This development could lead to the design of more efficient therapies for MPN treatment using currently available drugs, alone or in combination with other available treatments.

- We define a new MPN treatment that can arrest disease progression. This treatment could be extended to other hematological disorders that involve the degeneration of sympathetic fibers innervating the bone marrow.

Current development status

Tested in animal models

Desired business relationship

Patent licensing

Intellectual property status

Granted Patent
US10335380B2
United States of America

Granted Patent
JP6479818B2
Japan

Patent already applied for
EP2994119A1

Technology Owner

Spanish National Center for Cardiovascular Research (CNIC)

Research & Technology Organization

Additional information (attached documents)

Related keywords

  • Biological Sciences
  • Medicine, Human Health
  • Diagnostics, Diagnosis
  • Heart and blood circulation illnesses
  • Medical Research
  • Biology / Biotechnology
  • Cellular and Molecular Biology Technology
  • In vitro Testing, Trials Technology
  • Medical Health related
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Diagnostic services
  • Other ( Diagnostic related )
  • Therapeutic services
  • myeloproliferative neoplasms
  • hemotopoietic niche
  • bone marrow neuropathy
  • symatphetic fibers

About Spanish National Center for Cardiovascular Research (CNIC)

Research & Technology Organization from Spain

The Spanish National Center for Cardiovascular Research (CNIC) is a leading international research center dedicated to understanding the basis of cardiovascular health and disease and to translating this knowledge into improved patient care.

CNIC scientific area is organized into two departments focused on Basic Research and Clinical Research, fully interconnected through six multidisciplinary programs grouped into three research areas:

1 Vascular Pathophysiology
2 Myocardial Pathophysiology
3 Cell Developmental Biology

Our portfolio include biomarkers, genetic and diagnostic tools, animal models and treatments for cardiovascular, inflammatory and infectious diseases, among others. Some examples of our current projects include treatment for pulmonary hypertension, myeloproliferative diseases and trained immunity for prevention of infections. Regarding diagnosis, we are currently working on biomarkers for myocarditis, subclinical atherosclerosis and calcific aortic valve disease.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.